Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0049-000

Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of tocilizumab for the treatment of COVID-19. We also characterized which hospitalized patients are most likely to benefit from treatment with tocilizumab.

Tocilizumab may be efficacious in reducing the length of hospitalization and  the progression to the combined end point of mechanical ventilation or death. Treatment with tocilizumab in patients matching the characteristics of the patient populations in the RECOVERY and REMAP-CAP (2 of the largest and best-run) trials may yield the best outcomes. Evidence is lacking for patients with a compromised immune system, comorbidities, and concomitant bacterial infections.